‘Covid vaccines were PATHETICALLY tested…’: Whistleblower’s testimony reveals stunning details

Key Concepts

• Pharmacovigilance: The practice of monitoring the effects of medical drugs after they have been licensed for use, especially to identify and evaluate previously unreported adverse reactions.
• VAERS (Vaccine Adverse Event Reporting System): A passive surveillance system used in the U.S. to detect potential safety issues with vaccines.
• Masking: A statistical phenomenon where the signal of an adverse event for one vaccine is obscured because the baseline comparison data is inflated by reports from other vaccines.
• Empirical Bayesian (EB) Data Mining: A statistical method used to detect safety signals in large databases; the "Empirica Signal" software is a specific tool utilizing this method.
• Proportional Reporting Ratio (PRR): A statistical measure used to compare the frequency of an adverse event for a specific drug against the frequency of that event for other drugs in a database.
• V-safe: A CDC-managed active surveillance system using text messaging to collect health check-ins from vaccine recipients.
• Vaccine Safety Datalink (VSD): A collaboration between the CDC and healthcare organizations that uses electronic health records for active vaccine safety monitoring.

---

1. Critical Flaws in Safety Signal Detection

Dr. David Wiseman and Dr. Karl Jablonowski testified that the U.S. pharmacovigilance system failed during the COVID-19 vaccine rollout due to systemic statistical errors and administrative negligence.

• The Masking Problem: Dr. Wiseman explained that because the FDA compared COVID-19 vaccines against each other in the same database, the high volume of adverse event reports for one vaccine "masked" the signals of another. He used the analogy that if hemlock and arsenic are compared against each other rather than a non-toxic baseline, both appear innocuous.
• Failure to Implement Solutions: Dr. Anna Schuchat and Dr. William DuMouchel developed improved procedures to correct for masking within the "Empirica Signal" software. Despite being alerted to these methods, FDA officials reportedly asked Dr. Schuchat to "cease and desist" and claimed that implementing these fixes was beyond their capabilities or involved "unvalidated" tools.
• Redundancy and Negligence: The CDC abandoned its responsibility to perform PRR analyses, erroneously assuming the FDA’s Bayesian analysis was sufficient. This resulted in a total lack of a functional early warning system during the largest pharmaceutical deployment in history.

2. Deficiencies in Pre-Market Testing and Surveillance

Dr. Jablonowski highlighted that the vaccines were deployed with significant gaps in safety data, making robust post-market surveillance essential—a requirement he argues was never met.

• Lack of Pre-EUA Testing: He noted that the vaccines lacked studies on drug-drug interactions, cardiovascular toxicity, central nervous system toxicity, genotoxicity, and carcinogenicity. He argued that relying on the vaccines being safe without this data was "serendipitous" rather than scientific.
• V-safe Limitations: Dr. Jablonowski criticized V-safe for collecting "inconsequential data" (e.g., injection site pain, fatigue) while failing to track serious conditions like myocarditis. He noted that while 366 individuals typed "myocarditis" into the free-text fields of V-safe, the system was not designed to flag these reports effectively.
• Delayed Response: By the time the CDC updated its website to acknowledge heart inflammation risks, over 313 million doses had already been administered.

3. Methodologies and Frameworks

• Passive vs. Active Surveillance: The witnesses contrasted passive systems (VAERS), which rely on voluntary reporting, with active systems (V-safe, VSD), which proactively solicit data. They argued that both failed to provide the "enhanced surveillance" promised by standard operating procedures.
• Statistical Signal Detection: The testimony emphasized that regulators avoided the term "signal" to trivialize potential risks. The failure to use proper de-masking techniques meant that statistical signals for death, myocardial infarction, stroke, and dementia were effectively hidden from public view.

4. Key Arguments and Perspectives

• The "Betrayal of Our Time": Both witnesses characterized the failure of pharmacovigilance as a profound betrayal. Dr. Jablonowski stated, "Luck is not a pillar of public health," arguing that the government relied on chance rather than rigorous scientific oversight.
• Institutional Blindness: The witnesses argued that the FDA and CDC were not merely experiencing a "blind spot" but were actively ignoring warnings from internal experts and external researchers.
• Impact on Public Trust: Citing former colleagues Dr. Markx and Dr. Jernigan, the witnesses warned that the failure to detect and communicate serious health issues would irreparably damage public confidence in all vaccines, not just those for COVID-19.

5. Synthesis and Conclusion

The testimony concludes that the U.S. pharmacovigilance infrastructure was fundamentally broken during the COVID-19 vaccine rollout. The combination of statistical "masking," the abandonment of standard operating procedures (such as PRR analyses), and the failure to act on internal warnings from experts like Dr. Schuchat resulted in a system that was "completely blind" to adverse events. The witnesses advocate for an immediate correction of these deficiencies to restore the integrity of vaccine safety monitoring and to prevent the ongoing compromise of signal detection for future medical products.